RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains a Sector Perform rating on Inovio Pharmaceuticals (NASDAQ:INO) but lowers the price target from $11 to $8.
August 09, 2024 | 7:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital analyst Gregory Renza maintains a Sector Perform rating on Inovio Pharmaceuticals but lowers the price target from $11 to $8.
The lowered price target from $11 to $8 by RBC Capital suggests a less optimistic outlook for Inovio Pharmaceuticals, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100